In a nationwide group of Danish children, receipt of the live measles, mumps, and rubella (MMR) vaccine on schedule after vaccination for other common infections was associated with a lower rate of hospital admissions for any infections, but particularly for lower respiratory tract infections, according to a study in the February 26 issue of JAMA.
Childhood vaccines are recommended worldwide, based on their protective effect against the targeted diseases. However, studies from low-income countries show that vaccines may have nonspecific effects that reduce illness and death from non-targeted diseases, according to background information in the study. Such nonspecific effects of vaccines might also be important for the health of children in high-income settings.
Signe Sorup, Ph.D., of the Statens Serum Institut, Copenhagen, Denmark, and colleagues examined whether the live MMR vaccine was associated with lower rates of hospital admissions for infections among children in a higher-income setting (Denmark). The study included children 495,987 born 1997-2006 and followed from ages 11 months to 2 years. The recommended vaccination schedule was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) administered at ages 3, 5, and 12 months; and MMR at age 15 months.
There were 56,889 hospital admissions for any type of infection among the children in the study. The researchers found that receiving the live MMR vaccine after the inactivated DTaP-IPV-Hib vaccine was associated with a lower rate of hospital admissions for any infection. The association was particularly strong for lower respiratory tract infections and for longer hospital admissions. Children who received DTaP-IPV-Hib after MMR had a higher rate of infectious disease admission.
"The coverage with MMR is suboptimal in many high-income countries; in the present study, about 50 percent of children were not vaccinated on time. Physicians should encourage parents to have children vaccinated on time with MMR and avoid giving vaccinations out of sequence, because the present study suggests that timely MMR vaccination averted a considerable number of hospital admissions for any infection between ages 16 and 24 months," the authors write.
(doi:10.1001/jama.2014.470; Available pre-embargo to the media at http://media.
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Nonspecific Effects of Vaccines
In an accompanying editorial, David Goldblatt, M.B.Ch.B., Ph.D., of the UCL Institute of Child Health and Great Ormond Street Children's Hospital, London, and Elizabeth Miller, F.R.C.Path., of Public Health England, London, write that the WHO Strategic Advisory Group of Experts recently decided to revisit the issue of nonspecific effects of vaccines as part of its continued appraisal of important issues that could be relevant to inform global immunization policy.
"Systematic reviews of all available epidemiologic and immunologic evidence relevant to the issue of the nonspecific effects of vaccines on childhood mortality will be undertaken to decide whether current evidence is sufficient to lead to adjustments in policy recommendations or to warrant further scientific investigation. The study by Sorup et al is a further contribution to this body of literature. Although reanalysis of the available evidence is important, the ability to properly control for bias and confounding [factors that can influence outcomes] in observational studies is often limited, and without randomized controlled trials specifically designed to test the hypothesis, the issue of nonspecific effects of vaccines may remain subject to continuing debate."
(doi:10.1001/jama.2014.471; Available pre-embargo to the media at http://media.
Editor's Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Goldblatt reported receiving grants from, and serving on advisory boards for, GlaxoSmithKline, Sanofi Pasteur, Merck, and Novartis and serving on an advisory board for Pfizer. No other disclosures were reported.